Voyager Therapeutics, Inc. (VYGR) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Voyager Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.638 -- 00:00:05.703 Happy to be here and moderating this chat with Al Sandrock, CEO of Voyager. 00:00:05.703 -- 00:00:10.769 I'm sure everyone knows Al who's here listening in and got to know Al at his days at 00:00:10.769 -- 00:00:15.334 Biogen. So Al, maybe just give a quick overview of Voyager and then we can do a fireside 00:00:15.334 -- 00:00:17.236 chat and dive deeper into different programs. 00:00:17.236 -- 00:00:22.661 Yeah, great. So we are a multi-modality neurotherapeutics company 00:00:22.661 -- 00:00:26.063 where we're trying to optimize delivery. 00:00:26.626 -- 00:00:32.099 We have two platforms. We have a gene therapy platform platform where we're discovering 00:00:32.099 -- 00:00:37.709 capsids that cross the blood brain barrier after IV delivery. 00:00:37.709 -- 00:00:39.709 And 00:00:39.993 -- 00:00:45.022 that platform identifies not only the capsids, but then the receptors that 00:00:45.022 -- 00:00:50.724 the capsids leverage to get into the brain, we're now gonna be 00:00:50.724 -- 00:00:53.908 looking to see if we can use them as shuttles. 00:00:53.908 -- 00:00:58.974 And the first one of these is called ALPL, so you see that's already appearing on our 00:00:58.974 -- 00:01:04.040 pipeline chart there. So the idea is that these are validated receptors in the 00:01:04.040 -- 00:01:09.986 sense that we know they can carry large viral particle across the BBB. 00:01:09.986 -- 00:01:13.951 And so we're gonna make ligands against these receptors 00:01:13.951 -- 00:01:15.580 and conjugate 00:01:15.580 -- 00:01:17.580 oligonucleotides, 00:01:17.946 -- 00:01:22.277 put them on various protein therapeutics, and optimize delivery. 00:01:22.277 -- 00:01:26.909 So multi-modality focused on optimizing delivery. 00:01:26.909 -- 00:01:31.105 ...